Loading clinical trials...

Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus

Phase 1 Open-Label Two-Way Cross Over Study to Assess the Pharmacokinetic Profile of Two Formulations of PB1023 Injection Following a Single Dose Administered By Subcutaneous Injection in Adult Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT01427257•PhaseBio Pharmaceuticals Inc.

View on ClinicalTrials.gov

Summary

Primary objective: To compare the pharmacokinetic profile of PB1023 after a single dose administered by subcutaneous injection of two formulations (concentrations). Secondary objectives: To evaluate the safety and tolerability of two formulations of PB1023 Injection administered as a subcutaneous injection in adult subjects with T2DM. To evaluate the impact on the pharmacokinetic profile of PB1023 after a single 90 mg dose of formulation B (100 mg/mL) administered cold at 2 to 8°C by subcutaneous injection.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Willing and able to sign a written informed consent and follow all study related procedures.
•Males or post menopausal or surgically sterile females age 18 - 75 years of age inclusive.
•Diagnosed with T2DM for ≥ 6 months.
•HbA1c of ≥ 6.0% if diet and exercise controlled, or ≥5.8% if taking one or more glucose lowering agents
•Weight ≥ 45 kg and BMI ≤ 40 kg/m2
•In otherwise stable health except for T2DM (no clinically significant laboratory abnormalities, vital signs, ECG findings or clinically significant underlying disease that would put the subject at risk for participation in the study).
•Receiving stable doses of concomitant medications for 30 days prior to dosing.
•Criteria for Participation in Period 3 only: Received PB1023 Injection at 50 mg/mL and 100 mg/mL during Period 1 or 2 of the study and had adequate pharmacokinetic samples collected for evaluation of their pharmacokinetic profile.

Exclusion Criteria

•Currently taking Byetta® or Victoza®.
•Previously received PB1023 Injection other than under this study protocol.
•Known allergy or serious adverse effect to an approved or investigational GLP-1 receptor analog/agonist.
•Unstable cardiovascular disease defined as:
•* History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to the Screening visit.
•* Screening (duplicate supine reading) BP ≥ 160 mmHg (systolic) or ≥ 100 mmHg (diastolic).
•* Mean triplicate 12-lead ECG demonstrating QT interval (corrected) (QTc) \> 450 msec in males and \> 470 msec in females at the Screening visit, or a history or evidence of long QT syndrome.
•Based on contraindications/warnings identified with other GLP-1 receptor agonists, subjects will be excluded if they have:
•* History, symptoms or signs of pancreatitis or severe gastrointestinal disease (i.e., gastroparesis)
•* Personal or family history of medullary thyroid tumors or history of Multiple Endocrine Neoplasia Syndrome Type 2. Note: Abnormal serum calcitonin at screening will exclude the subject from participation.
+11 more criteria

Locations (1)

Prism Research

Saint Paul, Minnesota, United States

Key Dates

Start Date

February 1, 2012

Primary Completion Date

September 1, 2012

Completion Date

September 1, 2012

Last Updated

October 1, 2012

Enrollment

ACTUAL participants

Conditions

Diabetes Mellitus, Type 2

Interventions

Single Dose PB1023

DRUG

Single Dose PB1023

DRUG

Single Dose PB1023

DRUG

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

NCT06959901

Obesity and Diabetes Mellitus, Type 2Diabetes Prevention

View study

RECRUITINGNA

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

NCT06574035

Diabetes Mellitus, Type 2Depressive Symptoms+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 1, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus

Inclusion Criteria

Exclusion Criteria

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes

Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use

Prediction of Heart Failure and Cognitive Decline in Type 2 Diabetes

Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)